Subcommittee on Psychopharmacology
The Subcommittee on Psychopharmacology is a weekly meeting of all prescribing psychiatric staff. The committee serves to support and educate psychiatrists in work with complicated and generally “treatment-resistant” patients. The committee offers participating psychiatrists an opportunity to present clinical and countertransference challenges and to benefit from an educational and transferential “Third” to the doctor-patient pair. The committee serves a peer review function, in evaluating the treatment of patients prior to Case Conferences in the light of the standard of care, institutional priorities, performance improvement, and the principles of psychodynamic psychopharmacology. The committee also focuses on risk management and serves to review negative outcomes and near misses, incorporating PI methodologies such as Fishbone and Failure Mode Effects Causal Analysis. The committee will work directly with patients and their prescribers, in order to address and ameliorate treatment impasses in psychopharmacology. The committee also serves as an opportunity to disseminate recent developments in psychopharmacology, including new evidence, changes in the standard of practice, and new drug warnings. The committee interfaces with other systems within the treatment environment, including the medical office, the nursing department, information technology, and the pharmacy. In these interdepartmental engagements, the committee explores and evaluates systems-based practices in the service of education and performance improvement.
MD and DO
1. Review important evidence -based findings in psychopharmacology and relevant drug warnings (eg, from the FDA).
2. Assess current (individual and group) psychiatric practice patterns in the context of the standard of care and new evidence.
3. Integrate evidence on psychosocial/psychodynamic aspects of prescribing process.
4. Investigate institutional systems for delivery of pharmacologic care (including informatics) for system improvement.
John Azer, MD
Marina Bayeva, MD
Charlie Blomquist, MD
Vivian Chan, DO
Heather Forouhar, MD
Samar Habl, MD
Nick Holiday, MD
David Mintz, MD
Eric Plakun, MD
Kyle Shepard, DO
Margaret Parish, PhD
Austen Riggs Center Inc. confirms that Subcommittee members listed above, nor anyone involved in the planning of the CME event, has disclosed a potential conflict of interest.
The Austen Riggs Center designates this live activity for a maximum of 17 AMA PRA Category1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The Austen Riggs Center is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
This live activity is approved for up to 17 hours of AMA PRA Category 1 Credit(s)™, risk management study.
- 17.00 AMA PRA Category 1 Credit™
Accreditation Statement - Austen Riggs Center,Inc. is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
Designation Statement - Austen Riggs Center, Inc. designates this Live activity for a maximum of 17.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 17.00 Risk Management Study17.00 meet the criteria of the Massachusetts Board of Registration in Medicine's for risk management study.